R140
Showing 1 - 25 of 3,928
Depression After First-year of Tofacitinib in RA Patients
Recruiting
- Rheumatoid Arthritis
-
Prague, Czech Republic, Czechia
- +7 more
Nov 18, 2021
LUng CAncer focuS - Long-term Monitoring of Bronchogenic
Recruiting
- Lung Cancer
-
Brno, Czechia
- +6 more
Mar 7, 2022
Trifecta-Heart cfDNA-MMDx Study
Recruiting
- Heart Transplant Rejection
- MMDx diagnostic test
- +2 more
-
Los Angeles, California
- +9 more
Aug 2, 2022
Spondylitis, Ankylosing Trial in Worldwide (CC-99677, Placebo)
Active, not recruiting
- Spondylitis, Ankylosing
- CC-99677
- Placebo
-
Flagstaff, Arizona
- +139 more
Dec 9, 2022
Diabetic Peripheral Neuropathy Trial in Worldwide (LY3556050, Placebo)
Not yet recruiting
- Diabetic Peripheral Neuropathy
- LY3556050
- Placebo
-
Mesa, Arizona
- +54 more
Oct 3, 2023
Bioequivalence Study Trial in Verona (Diclofenac Sodium 140mg Medicated Plaster, Flector® topical plaster containing 180 mg of
Completed
- Bioequivalence Study
- Diclofenac Sodium 140mg Medicated Plaster
- Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenac
-
Verona, ItalyCRC Centro Ricerche Cliniche di Verona s.r.l. c/o Azienda Ospeda
Oct 7, 2020
Migraine Trial in Chicago, Saint Peters, Springfield (Erenumab-Aooe 140 MG/ML [Aimovig])
Recruiting
- Migraine
- Erenumab-Aooe 140 MG/ML [Aimovig]
-
Chicago, Illinois
- +2 more
Oct 23, 2020
Rheumatoid Arthritis Trial in Worldwide (MSB11456, EU-approved RoActemra)
Completed
- Rheumatoid Arthritis
- MSB11456
- EU-approved RoActemra
-
Haskovo, Khaskovo, Bulgaria
- +81 more
Jun 20, 2022
Episodic Migraine, Chronic Migraine Trial in Worldwide (Atogepant 60 mg)
Enrolling by invitation
- Episodic Migraine
- Chronic Migraine
- Atogepant 60 mg
-
Phoenix, Arizona
- +126 more
May 4, 2022
Refractory and/or Unexplained Chronic Cough Trial in Worldwide (BAY1817080, Placebo)
Completed
- Refractory and/or Unexplained Chronic Cough
- BAY1817080
- Placebo
-
Los Angeles, California
- +98 more
Jul 24, 2022
Episodic Migraine Trial in Worldwide (Atogepant 60 mg, Placebo)
Completed
- Episodic Migraine
- Atogepant 60 mg
- Placebo
-
Colton, California
- +113 more
Aug 12, 2022
Constipation Trial in Worldwide (, prucalopride)
Rheumatoid Arthritis Trial in Worldwide (Placebo to Upadacitinib, Methotrexate, Placebo to Methotrexate)
Completed
- Rheumatoid Arthritis
- Placebo to Upadacitinib
- +3 more
-
La Mesa, California
- +289 more
Dec 1, 2022
NSCLC, Urothelial Cancer Trial in Worldwide (Avelumab 800 mg in combination with pemetrexed / carboplatin, Avelumab 800 mg in
Active, not recruiting
- Non-small Cell Lung Cancer
- Urothelial Cancer
- Avelumab 800 mg in combination with pemetrexed / carboplatin
- +3 more
-
Tucson, Arizona
- +45 more
Oct 13, 2022
Acne Vulgaris Trial in Belgium, Canada, United States (IDP-126 Gel, IDP-126 Vehicle Gel, Epiduo® Forte Gel)
Active, not recruiting
- Acne Vulgaris
- IDP-126 Gel
- +2 more
-
Bryant, Arkansas
- +41 more
Jul 13, 2022
Parkinson Disease Trial in Worldwide (IPX203 140 mg, IPX203 210 mg, IPX203 280 mg)
Completed
- Parkinson Disease
- IPX203 140 mg
- +3 more
-
Phoenix, Arizona
- +97 more
Apr 5, 2022
Chronic Migraine Trial in Worldwide (Atogepant 30 mg, Atogepant 60 mg, Placebo)
Completed
- Chronic Migraine
- Atogepant 30 mg
- +2 more
-
Phoenix, Arizona
- +149 more
Jan 31, 2022
Type 2 Diabetes, Obesity, Overweight or Obesity Trial in Worldwide (Orforglipron, Insulin Glargine)
Recruiting
- Type 2 Diabetes
- +5 more
- Orforglipron
- Insulin Glargine
-
Muscle Shoals, Alabama
- +320 more
Apr 12, 2023
Renal Cell Carcinoma Trial in Worldwide (Nivolumab, Ipilimumab, Ipilimumab )
Active, not recruiting
- Renal Cell Carcinoma
- Nivolumab
- +2 more
-
Washington, District of Columbia
- +77 more
Jan 6, 2023